肺超声与高分辨率CT在系统性硬化症相关间质性肺病纵向监测中的比较:一项前瞻性队列研究
该单中心前瞻性队列纳入131例系统性硬化症(SSc)患者,其中83例完成肺超声(LUS)与高分辨率CT(HRCT)的纵向随访。基线LUS评分与HRCT间质性肺病(ILD)范围高度相关(Spearman's Rho=0.9087,P<0.0001),ΔLUS与ΔHRCT高度相关(Rho=0.9046,P<0.001),且ΔLUS可预测ILD进展(OR=1.874,P=0.003)或改善(OR=0.821,P<0.001)。LUS评分增加>5分预测ILD进展(AUC=0.98),降低>4分预测ILD改善(AUC=0.94)。
要点
- 基线LUS评分与HRCT的ILD范围高度相关(Rho=0.9087)。
- ΔLUS可预测ILD进展(OR=1.874)或改善(OR=0.821)。
- LUS评分增加>5分预测进展(AUC=0.98),降低>4分预测改善(AUC=0.94)。
核心结论
- LUS作为无创、可重复的工具,在识别SSc-ILD影像学进展或改善方面显示出临床相关潜力。
研究设计与样本
- 单中心前瞻性队列研究纳入131例SSc患者,其中83例完成LUS与HRCT的纵向随访。
- LUS采用半定量评分系统,覆盖72个肋间隙,总LUS评分为所有区域之和。
- HRCT上ILD范围绝对减少或增加≥5%分别定义为改善或进展。
主要发现
- 基线LUS评分与HRCT的ILD范围高度相关(Spearman's Rho=0.9087,P<0.0001)。
- 随访中ΔLUS与ΔHRCT高度相关(Spearman's Rho=0.9046,P<0.001),ΔLUS是ΔHRCT的显著预测因子(β=0.535,P<0.001)。
- ΔLUS是ILD进展(OR=1.874,P=0.003)或改善(OR=0.821,P<0.001)的显著预测因子。
- LUS评分增加>5分预测ILD进展(AUC=0.98),降低>4分预测ILD改善(AUC=0.94)。
关键数值与推荐
- ILD进展定义为HRCT上ILD范围绝对增加≥5%,改善定义为绝对减少≥5%。
- LUS评分增加>5分预测ILD进展的AUC=0.98,降低>4分预测ILD改善的AUC=0.94。
临床怎么用
- LUS可作为SSc-ILD纵向监测的无创、可重复工具,辅助识别影像学进展或改善。
- ΔLUS评分变化可提示ILD进展或改善,LUS评分增加>5分或降低>4分具有较高预测价值。
局限性
- 单中心研究,样本量有限(83例完成纵向随访)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Interstitial lung disease (ILD) constitutes the primary cause of mortality in patients with systemic sclerosis (SSc), necessitating precise radiographic monitoring to facilitate treatment decisions and improve prognosis. Lung ultrasound (LUS) shows promise for ILD screening, but its long-term effectiveness in tracking ILD change remains undetermined. METHODS: A total of 131 SSc patients were enrolled in this single-center prospective study, of whom 83 completed the longitudinal follow-up with both LUS and high-resolution computed tomography (HRCT). LUS was performed across 72 intercostal spaces using a semi-quantitative scoring system; total LUS score summed all zones. Improvement or progression was defined as an absolute reduction or increase of ≥5% in the extent of ILD on HRCT. RESULTS: The baseline LUS score correlated highly with ILD extent on HRCT (Spearman's Rho = 0.9087, P < 0.0001). Follow-up data indicated that changes in LUS score (ΔLUS) closely align with alterations in ILD extent on HRCT (ΔHRCT) (Spearman's Rho = 0.9046, P < 0.001), with ΔLUS score serving as a significant predictor of ΔHRCT (β = 0.535, P < 0.001). The ΔLUS score was identified as a significant predictor for ILD progression (OR = 1.874, P = 0.003) or improvement (OR = 0.821, P < 0.001). Specifically, an increase in LUS scores greater than 5 points predicted ILD progression (AUC = 0.98), while a decrease greater than 4 points predicted ILD improvement (AUC = 0.94). CONCLUSIONS: LUS, as a non-invasive, repeatable tool, shows clinically relevant potential for identifying radiographic progression or improvement in SSc-associated ILD (SSc-ILD).
引用
- Cao C, Chen J, Wang Y, et al. Lung ultrasound versus high-resolution computed tomography in the longitudinal monitoring of interstitial lung disease: a prospective cohort study in systemic sclerosis. Semin Arthritis Rheum. 2026. PMID: 42710165. doi:10.1016/j.semarthrit.2026.153069
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。